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Nutrition Support in Acute Kidney Injury !
Jane M. Gervasio, Wesley P. Garmon, and Michael Holowatyj !
Butler University, College of Pharmacy and Health Science, Indianapolis, Indiana !
Abstract !
Acute kidney injury is a frequent complication affecting many hospitalized patients and is 
associated with increased morbidity and mortality. Acute kidney injury often occurs in 
conjunction with critical illness, which is a hypermetabolic state presenting with hyperglycemia, 
insulin resistance, hypertriglyceridemia, and increased protein catabolism. In addition to 
addressing these changes, the clinician should evaluate the important nutrition implications of 
decreased kidney function. These include vitamins, electrolytes, minerals, trace elements, and the 
presence and type of renal replacement therapy. Optimal nutrition management in acute kidney 
injury includes providing adequate macronutrient support to correct underlying conditions and 
prevent ongoing loss, supplementing micronutrients and vitamins during renal replacement 
therapy, and adjusting electrolyte replacement based on the degree and extent of renal 
dysfunction. !!!!
Acute renal failure is a common complication affecting approximately 5% of hospitalized 
patients and 10%–30% of patients managed in intensive care units. No universal definition for 
acute renal failure currently exists, although the Acute Dialysis Quality Initiative (ADQI) has 
proposed updating the nomenclature from acute renal failure to the more current acute kidney 
injury (AKI). In addition, ADQI has proposed a consensus definition for AKI summarized by the 
acronym RIFLE. RIFLE contains 3 stages of kidney injury stratified by severity (risk, injury, and 
failure) and 2 outcomes (loss and end-stage kidney disease). These criteria are based on the 
combined measurements of serum creatinine or glomerular filtration rate and urine output. !
AKI is associated with a sudden decline of glomerular filtration rate with an accumulation of 
metabolic waste products (eg, urea), toxins, and drugs along with alterations in the intrinsic 
functions of the kidney. The kidneys are responsible for many regulatory functions, including 
acid-base equilibrium, fluid and electrolyte balance, gluconeogenesis, and secretion of the 
hormones erythropoietin and the conversion of vitamin D3 into its active form. These functions 
are impaired to varying degrees based on the extent, magnitude, and duration of the AKI. Arising 
and escalating dysfunction of these processes results in necessary alterations in the patient’s 
fluid, macronutrient, and micronutrient management. !!!
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Nutrient Metabolism !
Glucose 
The most common glucose disorders encountered in critically ill patients are hyperglycemia and 
increased insulin resistance. Hepatic glycogenolysis and gluconeogenesis are increased from the 
actions of the catabolic hormones (glucagon, epinephrine, and cortisol). Critically ill patients 
have decreased insulin-dependent glucose utilization in skeletal muscle and adipose tissue, which 
contributes to insulin resistance and hyperglycemia.1 Under normal conditions, the kidneys 
contribute 15%–25% of gluconeogenesis and approximately 10%–20% of glucose uptake, and 
they are responsible for 30% of insulin catabolism.2,3 Patients with AKI are prone to exacerbated 
insulin resistance due to decreased renal gluconeogenesis and decreased hormonal clearances of 
insulin and glucagon. The exact contribution of the altered carbohydrate metabolism in AKI in 
critically ill patients is unclear; however, the severity of insulin resistance in AKI is correlated 
with mortality and remains significant after correction for severity of illness, cortisol, diabetes, 
and other patient-related factors.4 !
Lipid 
Impaired lipolysis in AKI results in an increase in plasma triglycerides, very low-density 
lipoproteins, and low-density lipoprotein, whereas the total circulating cholesterol and high-
density lipoprotein are decreased.5 AKI also results in decreases of hepatic triglyceride lipase and 
peripheral lipoprotein lipase activity by 50%, increasing the risk of hypertriglyceridemia,3 and 
the activity of lipoprotein lipase is further decreased if metabolic acidosis is present.6 With these 
lipid metabolism derangements, parenteral administration of lipids has shown to have reduced 
clearance in patients with AKI. These changes can partially be attenuated by the administration 
of amino acids and glucose.5 Although the clearance of lipids is decreased in AKI, fatty acid 
oxidation is preserved; lipids remain an important energy source in this patient population. !
Protein 
The liver uses amino acids, lactate, and glycerol for glucose and acute-phase protein production 
in critical illness. Although critical illness is associated with an increase in protein catabolism, 
AKI alone does not always result in a catabolic state. However, if both AKI and critical illness 
are present, the result is a prolonged intense state of catabolism.3 Metabolic acidosis in AKI, 
along with increased insulin resistance in critical illness, further promotes increased protein 
catabolism. Transport of amino acids into skeletal muscle is altered, and synthesis of proteins, 
other than visceral and acute-phase proteins, is inhibited.7 The ability to correct these protein 
deficiencies with exogenously administered amino acids is frequently insufficient to correct the 
catabolic state, but supplementation may decrease the net rate of body loss.7 The clearance of 
most amino acids in these patients is increased up to 1.3–1.8 g/kg/d.8 A few noteworthy changes 
in amino acid concentrations occur in AKI. The serum concentrations of phenylalanine, 
methionine, taurine, and cysteine are elevated, whereas serum valine and leucine levels are 
decreased. Also, several non–essential amino acids (EAA; tyrosine, arginine, and glutamine) 
become conditionally essential or indispensable. Last, the conversion of phenylalanine to 
tyrosine in these patients becomes inadequate.9 
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With this understanding, specialty amino acid solutions were marketed for use in patients with 
AKI; however, no appreciative outcome differences were observed. Mirtallo and colleagues10 
compared EAA solutions with a combination of EAA and non-EAA solutions in 45 patients 
receiving parenteral nutrition (PN) but not receiving dialysis. Although significant differences 
were observed between the groups with respect to urea nitrogen appearance and net protein 
utilization, these differences did not result in any significant differences in estimated protein 
nitrogen balance or mortality. Other studies have investigated various combinations of specialty 
amino acid administration, including hypertonic glucose plus EAA solution to hypertonic 
glucose alone, high EAA delivery to low EAA delivery, and glucose plus EAA solutions plus 
histidine to glucose plus standard amino acid solution to glucose plus standard amino acid 
solution plus lipids.11-14 Recovery from AKI and an increased rate of survival on dialysis were 
observed in the groups receiving hypertonic glucose plus EAA vs hypertonic glucose alone, but 
again, no outcome differences were observed between any of the specialty amino acid solutions. 
At this time, the international and national guidelines do not support the use of the specialty renal 
amino acid products.14-16 !
Energy Expenditure !
Provision of energy and protein in adequate amounts of nutrients may help prevent protein 
energy wasting (PEW) by promoting tissue repair and supporting the immune system. The 
kidneys, although only approximately 0.5% of total body mass, are responsible for nearly 10% of 
the resting energy expenditure. AKI, without critical illness, does not appear to have a direct 
effect on the resting energy expenditure.17 In patients with AKI and sepsis, metabolic rates were 
found to be increased compared with nonseptic patients with normal renal function. The increase 
in metabolic rates also persisted after correction for increases in metabolic demand secondary to 
fever. Energy expenditure requirements are therefore a function of the severity of the underlying 
conditions, prior nutrition status, and comorbidities rather than AKI alone.18 AKI is often 
associated with critical illness, which is associated with significant changes to the metabolic rate. 
These concomitant disorders make it difficult to distinguish AKI’s precise contribution to 
metabolic disorders. !
Critical illness is a hypermetabolic state with increases in energy expenditure proportional to the 
amount of stresses experienced.19 In the AKI population, the maximal metabolic energy 
expenditure is limited to approximately ~130% of normal.17 In critically ill patients, plasma 
concentrations of catecholamines, cortisol, and glucagon are increased along with inflammatory 
mediators and cytokines, resulting in increased skeletal muscle catabolism, insulin resistance, 
and increased gluconeogenesis/glycogenolysis. These changes are thought to be beneficial in the 
acute phase to provide energy and substrates for protein synthesis and replication in immune 
cells, as well as hepatic and gastrointestinal tissue. However, during prolonged intense stress, a 
severe depletion of body stores may adversely affect recovery and may be detrimental to 
morbidity and mortality.1 !
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Nutrition Goals !
The goals of nutrition support in patients with AKI are consistent with the goals for critically ill 
patients and include delivery of energy, protein, and micronutrients to prevent PEW; preservation 
of lean body mass; maintenance of nutrition status; avoidance of further metabolic 
derangements; enhancement of wound healing; support of immune function; attenuation of the 
patients’ inflammatory status; and improvement of the oxygen radical scavenging system and of 
endothelial function and reduction in mortality.16,20 !
Enteral nutrition (EN) is the preferred method of nutrition delivery in patients with a functioning 
intestine. PN should be reserved for those patients unable to tolerate EN or if EN does not meet 
their energy and protein requirements. !
Nutrition Assessment !
PEW is the standard terminology established by the International Society of Renal Nutrition and 
Metabolism to define the recognized increased energy expenditure, muscle loss, and malnutrition 
associated with AKI.21 PEW in AKI results from nonspecific inflammatory processes, catabolic 
illnesses, nutrient losses from dialysis, metabolic acidosis, and endocrine disorders, including 
resistance to insulin, growth hormone, and insulin-like growth factor 1 (IGF-1); 
hypergluconemia; and hyperparathyroidism.21 In addition, comorbid conditions and 
complications, including trauma, thermal injury, surgery, and infections, further worsen the 
patient’s nutrition status. Hospital length of stay; complications, including sepsis and 
cardiovascular and respiratory failure; and hospital mortality significantly increase when 
nutrition status is impaired.22 Accurate assessment of the patient’s nutrition status is imperative. !
PEW is diagnosed if 3 characteristics are present: (1) low serum levels of albumin, prealbumin, 
or cholesterol; (2) reduced body mass (low or reduced body or fat mass or weight loss with 
reduced intake of protein and energy); and (3) reduced muscle mass (muscle wasting or 
sarcopenia, reduced mid-arm muscle circumference). However, diagnosis of PEW in patients 
with AKI may be challenging. Although hypocholesterolemia and low serum albumin 
concentrations are suggested as nutrition markers and have been linked to survival in AKI, well-
known limitations with these biochemical markers preclude them from being truly diagnostic. 
Prealbumin is renally excreted, thereby decreasing its utilization as a nutrition marker in patients 
with AKI. In addition, a negative acute-phase response due to inflammation is associated with 
suppression of prealbumin. Associated edema and fluid shifts from the AKI may alter somatic 
protein test (eg, mid-arm muscle circumference), making it difficult to obtain an accurate 
measurement.23 !
Recognizing these complications, alternative markers have been suggested to help identify 
patients in whom nutrition support should be considered. IGF-1 has been investigated as a 
mortality predictor in patients with AKI and as a specific marker for malnutrition in patients 
undergoing hemodialysis, but limited information precludes its recommendation as a routine  
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Table 1. Nitrogen Balance, Urea Nitrogen Appearance, and Protein Catabolic Rate Equations !
Nitrogen balance, g/d = Nitrogen intake - UUN + nonurea urinary nitrogen (2 g/d) + fecal nitrogen (2 g/d) 
Urea nitrogen appearance, g/d = UUN + [(BUN2 - BUN1) × 0.6 × BW1] + [(BW2 - BW1) × BUN2] !
where net protein breakdown = UNA × 6.25; BUN1 = initial concentration of BUN, postdialysis, g/L; BUN2 = final 
concentration of BUN, predialysis, g/L; BW1 = postdialysis weight, kg; BW2 = predialysis weight, kg. !
PCR, g/d = UNA × 6.25 !
UUN, urinary urea nitrogen; BUN, blood urea nitrogen; BW, body weight; PCR, protein catabolic rate. !
nutrition marker.24 C-reactive protein, a marker of inflammation, may be useful in identifying 
patients at high risk for mortality and, used in conjunction with visceral protein markers (eg, 
albumin, prealbumin), can improve patients’ nutrition assessment.15 !
Nitrogen balance (measurement of nitrogen intake minus nitrogen output), urea nitrogen 
appearance (UNA; measurement of the net rate of protein catabolism), and protein catabolic rate 
(PCR; measurement of net protein degradation) may be measured to assess the patient’s protein 
breakdown (Table 1). For an accurate determination, the standard method for measuring a 
patient’s nitrogen balance requires a creatinine clearance of >50 mL/min/1.73 m,2 making 
utilization of the nitrogen balance in patients with AKI difficult. In patients with AKI, 
ascertaining the UNA is less laborious and may be more accurate; however, protein intake 
fluctuation and varying catabolic presentations may result in calculated erroneous results.9,25 !
To best assess the nutrition status of patients with AKI, the clinician must recognize the inherent 
complications associated with the anthropometric markers, implementing good clinical judgment 
and an appreciation for the patient’s history, presentation, and clinical course. !
Nutrient Requirements !
Macronutrients 
Energy delivery in patients with AKI is recommended from 25–35 kcal/kg/d.15,16 Nutrition 
support should be based on estimated metabolic stress and protein energy requirements. In 
patients presenting with stage 1 AKI (see Table 2),26 caloric requirements are based on their 
underlying disease state or complication because stage 1 AKI has limited effects on the patient’s 
energy expenditure. Patients presenting with stage II or III AKI (see Table 2),26 however, will 
usually have greater caloric requirements because of the advanced disease presentation and 
concomitant underlying disease state or complication. !
Higher caloric delivery has been studied but does not appear to improve patient outcomes. 
Fiaccodori and colleagues23 studied patients with AKI and hemodialysis receiving either higher 
calorie PN (40 kcal/kg/d) or lower calorie PN (30 kcal/kg/d). Nitrogen intake for both groups 
was 0.25 g/kg/d. Patients receiving the higher PN did not show a significant improvement in 
their estimated nitrogen balance, PCR, or urea generation rate but did present with increased  
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Table 2. Staging System for Acute Kidney Injury (AKI) 
AKI Stage Serum Creatine      Urine Output 
I  Increase in serum creatine ≥0.3 mg/dL or increase to  <0.5 mL/kg/h for more than 6 
  ≥150%-200% (1.5- to 2-fold) from baseline   hours 
II  Increase in serum creatine >200%-300% (>2- to 3-fold) <0.5 mL/kg/h for more than 12 
  from baseline      hours 
III  Increase in serum creatine to >300% (>3-fold) from  <0.3 mL/kg/h for more than 24 
  baseline or serum creatine ≥4 mg/dL with an acute increase hours, or anuria for more than 12 
  of at least 0.5 mg/dL     hours !
Adapted from Mehta et al.26 !
metabolic complications, including increased serum triglycerides and glucose concentrations, 
and insulin requirements. !
Protein delivery in patients presenting with stage I AKI should be based on the patient’s 
underlying disease or complication. Lowering the protein delivery may be necessary to avoid 
azotemia. However, restricting protein or delivering inadequate amounts of protein is not advised 
because it increases the patient’s risk for protein malnutrition and associated complications.25 
Advanced presentations of AKI in acutely ill patients usually require renal replacement therapy 
(RRT), including intermittent hemodialysis (IHD) and continuous RRT (CRRT), because of the 
catabolism associated with the critical illness, metabolic acidosis, and increased insulin 
resistance. Recommendations for protein delivery in patients with AKI receiving RRT range 
from 1.5–2.5 g/kg/d and depend on the patient’s severity of AKI, the underlying disease states 
and complications, and the type of RRT employed.14-16 Patients receiving CRRT demonstrate 
positive nitrogen balance when dosages of 1.8–2.5 g/kg/d of protein are delivered, whereas 
protein dosages from 1.5–2.0 g/kg/d may be sufficient for patients undergoing IHD.15 !
Electrolytes/Minerals 
The kidneys are responsible for regulating many electrolytes,27 vitamins, and trace elements. The 
breakdown in electrolyte and micronutrient regulation along with the addition of RRT produces a 
complex clinical scenario. It is generally recommended to withhold or minimize exposure to 
these renally regulated electrolytes and micronutrients in patients with AKI who are not 
receiving RRT. However, the initiation of RRT and/or nutrition support therapy (NST) can have a 
dramatic effect on consumption and utilization of many micronutrients. Brown and Compher,15 
in conjunction with the American Society of Parenteral and Enteral Nutrition, published 
guidelines for NST in patients with AKI. The recommendations for electrolyte and micronutrient 
management were to adjust intake based on serum concentration monitoring. The 
recommendation was provided as grade D, suggesting limited data to clearly delineate further 
recommendations. !
Potassium 
Potassium, a monovalent cation, is found extensively in the intracellular compartment and is 
tightly regulated by the kidney.27 Potassium is important in many aspects of cellular homeostasis, 
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and imbalance can have severe adverse effects, including arrhythmias, rhabdomyolysis, and 
death. Along with primarily renal regulation, many other factors may influence serum potassium 
concentrations, including losses via the gastrointestinal (GI) tract and plasma pH. With regards to 
patients with AKI, it is common to see hyperkalemia due to decreased renal excretion, acidosis, 
and GI losses. In general, in patients with AKI not receiving RRT, it is acceptable to withhold 
potassium until/unless the patient becomes hypokalemic. In the setting of hypokalemia, there are 
multiple approaches to the management of potassium for patients receiving RRT. Many patients 
may simply be managed by manipulation of the dialysis prescription. In the event of continued 
hypokalemia after altering the dialysis prescription, as needed replacement may be administered. 
Modest bolus doses of potassium, 10–20 mEq for mild to moderate hypokalemia (2.5–3.4 mEq/
L) and 20–40 mEq for severe hypokalemia,27,28 should be considered a starting point. Continuous 
daily boluses of potassium may warrant an adjustment to the PN or NST but should also be 
modestly added. With many factors affecting serum potassium concentrations and endless 
clinical case scenarios, sound judgment is imperative. !
Calcium 
Calcium has many important physiologic roles, and AKI can dramatically alter a patient’s 
calcium regulation. Calcium is tightly regulated by parathyroid hormone (PTH) and activated 
vitamin D3, along with the kidneys. The final step of activation for the conversion to 1,25 
dihydroxy vitamin D3 occurs in the kidney and is extensively limited in patients with AKI. This 
loss of vitamin D3 activity can lead to a lack of enteral calcium absorption. Additional causes for 
hypocalcemia in AKI include hyperphosphatemia, as well as significant losses from RRT effluent 
and citrate anticoagulation.29 Subsequently, hypocalcemia is commonly observed in patients with 
AKI, which can result in hypotension and clotting disorders. As with potassium, there are 
multiple approaches for the management of hypocalcemia in patients with AKI depending on the 
presence and type of RRT. Patients receiving IHD may require manipulation of the dialysis 
prescription. For patients receiving CRRT, the postdialysis circuit continuous infusion of calcium 
may be adjusted based on serum ionized calcium concentrations. For patients not on CRRT and 
requiring additional calcium, recommendations established by Kraft and colleagues27 may be 
followed. These recommendations are as follows: (1) for mild to moderate hypocalcemia (total 
serum calcium concentration of <8.6 to 7.5 mg/dL or ionized calcium concentration of <1.1 to 
0.9 mmol/L), patients should be administered calcium gluconate 1–2 g intravenously over 30–60 
minutes, repeating every 6 hours as needed. (2) For symptomatic or severely hypocalcemic 
patients (total serum calcium concentration of <7.5 mg/dL or ionized calcium concentration of 
<0.9 mmol/L), either calcium gluconate 3 g intravenously or calcium chloride 1 g intravenously 
should be administered over 10 minutes. If calcium chloride is the chosen salt, it should be 
administered via a central line only to prevent extravasation and tissue necrosis. !
Phosphorus 
Phosphorus is an important intracellular electrolyte necessary in cellular metabolism and the 
production of adenosine triphosphate (ATP), necessary for cardiac and diaphragmatic 
contraction. Phosphorus, like calcium, is also regulated by vitamin D, PTH, and the kidneys; in 
patients with AKI, hyperphosphatemia is commonly observed. Hyperphosphatemia not only  
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Table 3. Advantages and Disadvantages of the Pharmacological Agents Available for the Treatment of 
Hyperphosphatemia 
Products   Advantages Disadvantages 
Calcium salts  Effective Possible increase in serum calcium concentrations; hypercalcemia 
   Low cost 
Aluminum hydroxide Effective Aluminum concentrations may accumulate; aluminum toxicity 
   Low cost Not recommended for long-term usage 
Magnesium hydroxide Effective Possible increases in serum magnesium concentration; 
   Low cost hypermagnesemia. May cause diarrhea. 
Sevelamer hydrochloride Effective Expensive; hypercalcemia associated with long-term usage 
     Nausea/vomiting (~20%) 
Lanthanum carbonate Effective Expensive; hypercalcemia associated with long-term usage 
     Nausea/vomiting (~10%) 
!
exacerbates existing hypocalcemia but may also lead to calcium-phosphate crystal deposition in 
soft tissues, resulting in additional or worsening organ dysfunction. Treatment of phosphorus 
disorders in patients with AKI can vary widely depending on the type and presence of RRT, as 
well as the presence or lack of NST. Patients not receiving RRT typically require phosphorus 
restriction and, in many cases, phosphate binders (Table 3). IHD commonly results in 
hyperphosphatemia as there is not sufficient dialysis time to remove adequate amounts of 
phosphorus. Conversely, patients receiving CRRT typically have hypophosphatemia and require 
supplemental phosphorus. It is common to replace phosphorus on an as needed basis in 
increments of 15–20 mmol per dose. !
Magnesium 
Also highly regulated by the kidney, magnesium performs a variety of different roles in vivo. 
Magnesium is an integral cofactor for many enzyme systems, such as the Na/K ATPase pump, 
which is responsible for maintaining the normal potassium gradient. In the setting of AKI, 
hypermagnesemia may occur due to a lack of renal excretion. If severe, hypermagnesemia may 
lead to exacerbation of hypotension. Withholding magnesium is generally advised for patients 
with AKI not receiving RRT. In the setting of RRT, patients will require supplementation. Some 
clinicians suggest supplementation in the form of continuous infusion, but as needed replacement 
boluses of 2–4 g magnesium sulfate may also be a viable option.30 !
Micronutrients 
Much discussion and research regarding micronutrients is focused on low serum concentrations. 
The interpretation of these “low” serum concentrations should be tempered with the 
thoughtfulness that the acute-phase response commonly occurs in patients with AKI.31-33 This 
activation of the acute-phase response causes a rapid redistribution of carrier proteins (eg, retinol 
binding protein) for vitamins as well as the distribution of trace elements into the tissues (eg, 
selenium and zinc). This response is in an effort to distribute these critical elements and 
compounds to the tissues for incorporation into enzyme systems. These enzyme systems have a 
plethora of actions, from tissue reconstruction to immunologic enhancement. In the setting of 
AKI, the homeostasis of these micronutrients can be drastically altered, resulting in a 
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complicated picture. Supplementation of micronutrients should be initiated preemptively only 
when quality research supports its implementation and reliable dosages are recommended. !
Vitamins !
B Vitamins: Folic Acid/Pyridoxine/Thiamine 
Loss of water-soluble vitamins is common in patients receiving RRT, and supplementation may 
be required. Several studies have assessed B vitamin needs in AKI patients receiving CRRT. 
Fortin and colleagues34 studied CRRT clearance and removal of folic acid and pyridoxal-5′-
phosphate by analyzing the daily concentrations of each micronutrient. The investigators found 
significant losses of both folic acid and pyridoxal-5′-phosphate and recommended 
supplementation of each micronutrient to a minimum of 2–3 times the Recommended Daily 
Allowance (RDA). In patients with AKI receiving CRRT, folate 1 mg daily and pyridoxine 10 
mg daily are recommended. !
The dose of thiamine for patients undergoing CRRT varies widely in the literature. Berger and 
colleagues35 demonstrated losses of ~4 mg/d of thiamine. Fiaccadori and colleagues36 suggested 
thiamine losses of 1.5 times the standard dose contained within typical intravenous multivitamin 
(MVI) preparations, whereas Chiolero and Berger37 recommended supplementing thiamine at a 
dose of 100 mg/d in patients receiving CRRT. This represents a wide range in dosing 
possibilities. As thiamine is a water-soluble vitamin with little toxicity, it would be reasonable to 
provide 25–100 mg per day of thiamine supplementation in patients receiving CRRT. !
Vitamin C 
Vitamin C has been found to be problematic in patients with AKI. Vitamin C is converted to 
oxalate, which can accumulate in renal tubules as a toxin, leading to renal dysfunction.38,39 
Recognizing this complication, it is recommended to not exceed 100 mg/d of vitamin C in 
patients with AKI not receiving RRT in an effort to minimize risk of further renal injury. Story 
and colleagues40 compared serum concentrations of multiple vitamins and trace elements in 8 
patients receiving CRRT with a “normal” control group. The CRRT group had lower 
concentrations of selenium, zinc, vitamin E, and vitamin C. The CRRT group was also found to 
have vitamin C, copper, and chromium in the ultrafiltrate. With this extra loss of vitamin C from 
CRRT, it may be permissible to increase vitamin C to 200 mg/d in patients receiving CRRT. 
However, dosages of vitamin C >250 mg/d are not advised because of the risk of secondary 
oxalosis and further renal injury.20 !
Vitamin A 
Vitamin A has been linked to toxicity in patients with renal dysfunction. Gleghorn and 
colleagues41 reported 3 cases of vitamin A toxicity with associated hypercalcemia in patients 
with renal failure receiving an MVI in the PN. The hypercalcemia resolved with the removal of 
vitamin A delivery. The reported dosage these patients were receiving was 1500 mcg/d of retinol. 
The current formulation of injectable MVI provides 990 mcg/d, which is slightly above the 
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dietary reference intake of 700 mcg/d in women and 900 mcg/d in men. Changes to vitamin A 
dosage delivery are not recommended but warrant monitoring for patients with AKI. !
Trace Elements 
Deficiency in trace elements can lead to an imbalance in the regulation of oxidative stress, which 
is important in combating the acute-phase reaction. Trouble arises in the patient receiving CRRT
—because trace elements are naturally small molecules, they may be easily removed during 
therapy. However, much like PN, CRRT dialysate fluids may also contain trace element 
contaminants. As discussed below, depending on the amount of contamination, this may impart a 
positive or negative balance during CRRT. !
Zinc 
Multiple reports of achieving a positive zinc balance have been reported in patients receiving 
CRRT.30,35 This has been postulated to occur due to zinc contamination of CRRT dialysate and 
citrate use as an anticoagulant. Thus, supplementation of zinc beyond the standard dose 
contained within the nutrition support prescription is not recommended. !
Selenium 
Conversely, selenium deficiencies have been reported due to CRRT removal, with deficits 
estimated from 35–91 mcg/d.35,41 Cumulative losses of selenium via CRRT are likely to result in 
deficiency if not corrected. An additional 100 mcg/d of selenium in addition to the standard 
multiple trace element preparation is recommended.20 !
Copper 
Research studies have suggested a negative copper balance of approximately 400 mcg/d in renal 
failure patients receiving CRRT.35,41 The suggested Dietary Reference Intake (DRI) is 300–500 
mcg/d.42 The standard multiple trace element preparation delivers 1000 mcg/d, which exceeds 
the DRI and the additional losses attributed to CRRT; therefore, additional supplementation is 
not necessary. !
Conversely, it is quite common for critically ill patients to present with hepatobiliary dysfunction 
(defined as a total bilirubin >3 mg/dL). Many clinicians advocate the removal of copper from PN 
in patients with hepatobiliary dysfunction to prevent toxicity. Thus, depending on the clinical 
situation, it may be prudent to omit copper delivery. !
Aluminum 
Potassium phosphates, sodium phosphates, and calcium gluconate have been identified as major 
contributors to aluminum contamination in PN.43 Brown and colleagues44 evaluated the risk of 
aluminum exposure in AKI patients. The results indicated that few patients (7/36) were exposed 
to excessive amounts of aluminum, defined as aluminum content >5 mcg/kg/d. The investigators 
found that calcium gluconate contributed the greatest amount of aluminum to the PN product. It 
is prudent to recognize that patients with AKI receiving PN are at higher risk for aluminum 
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accumulation, but most patients will not receive excessive exposure to aluminum from the PN 
formulation. !
Conclusion !
Complications from AKI and critical illness include increased metabolism, hyperglycemia, 
insulin resistance, hypertriglyceridemia, and increased protein catabolism. Nutrition support is 
frequently required, and appropriate nutrition delivery, tailored to the patient’s clinical 
presentation, is imperative. Energy requirements must be assessed, and macronutrient and 
macronutrient adjustments, based on the presence and type of renal replacement therapy, must be 
implemented. !
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